Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab consolidation after CCRT in ESCC
NCT04514835Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Dec 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04514835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04514835.